Dr. Sandra Sanchez-Roige explains how large-scale studies of genome variations have identified risk locations for substance use disorders. She also discusses the importance of converting these signals from the genome into biological understanding of mechanisms and vulnerabilities which may provide a path forward for the development of novel treatments.

Dr. Volkow, Director of the National Institute on Drug Abuse (NIDA) and leading authority on substance use and the science of addiction, explains the origins of the fentanyl crisis, the challenges of treating overdoses, and offers her assessment of psychedelics as therapies for psychiatric illness, as well as current evidence on the dangers of regular cannabis use among young people.

Dr. Sarah Lisanby has been deeply involved in developing and improving the safety of life-saving neuromodulatory treatments including electroconvulsive therapy (ECT) and magnetic seizure therapy (MST) for severe psychiatric illness.